Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | TK1 | P04183 | 4/20 | 0.53 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.53 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.53 |
| ▸ | TK2 | O00142 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | BLM | P54132 | 1/20 | 0.48 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL601434 | 1.00 | LMNA (0.56) | LMNASMN1; SMN2TK1ALOX12ADRA1A | |
| SCHEMBL13944236 | 1.00 | LMNA (0.56) | LMNASMN1; SMN2TK1ALOX12ADRA1A | |
| SCHEMBL610031 | 1.00 | LMNA (0.56) | LMNASMN1; SMN2TK1ALOX12ADRA1A | |
| SCHEMBL13944238 | 0.88 | LMNA (0.45) | LMNASMN1; SMN2TK1ALOX12ADRA1A | |
| SCHEMBL4169178 | 0.87 | TK1 (0.53) | LMNASMN1; SMN2TK1ALOX12ADRA1A | |
| SCHEMBL6270422 | 0.87 | TK1 (0.70) | LMNASMN1; SMN2TK1ALOX12ADRA1A | |
| SCHEMBL868882 | 0.87 | TK1 (0.70) | LMNASMN1; SMN2TK1ALOX12ADRA1A | |
| SCHEMBL15740180 | 0.87 | TK1 (0.70) | LMNASMN1; SMN2TK1ALOX12ADRA1A | |
| SCHEMBL18032569 | 0.87 | TK1 (0.70) | LMNASMN1; SMN2TK1ALOX12ADRA1A | |
| SCHEMBL18032571 | 0.87 | TK1 (0.70) | LMNASMN1; SMN2TK1ALOX12ADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 102 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1027061-B1 | IMINE-FORMING POLYSACCHARIDES, PREPARATION THEREOF AND THE USE THEREOF AS ADJUVANTS AND IMMUNOSTIMULANTS | GALENICA PHARMACEUTICALS INC (US) | 2005-05-25 | — | — | EP | claimed |
| US-20020150585-A1 | Use of imine-forming polysaccharides as adjuvants and immunostimulants | GALENICA PHARMACEUTICALS, INC. | 2002-10-17 | — | — | US | claimed |
| US-20020042392-A1 | Uracil reductase inactivators | SMITHKLINE BEECHAM CORPORATION | 2002-04-11 | — | — | US | claimed |
| US-6297223-B1 | ADMINISTERING 5-SUBSTITUTED- OR 5,6-DIHYDRO-5-SUBSTITUTED-URACIL DERIVATIVE OR A PRODRUG THEREOF; IN CONJUNCTION WITH 5-FLUOROURACIL OR PRO-DRUG THEREOF. | GLAXO WELLCOME INC. | 2001-10-02 | — | — | US | claimed |
| US-6221852-B1 | INACTIVATORS OF URACIL REDUCTASE. | GLAXO WELLCOME INC. | 2001-04-24 | — | — | US | claimed |
| EP-0356166-B1 | Therapeutic nucleosides | WELLCOME FOUND (GB) | 1994-04-20 | — | — | EP | claimed |
| WO-1994005686-A1 | ANOMERISATION PROCESS | UNIVERSITY OF BIRMINGHAM (GB) | 1994-03-17 | — | — | WO | claimed |
| US-5198539-A | Viricides | BURROUGHS WELLCOME CO. (US) | 1993-03-30 | — | — | US | claimed |
| EP-0522128-A1 | WATER-DISPERSIBLE TABLETS. | WELLCOME FOUND (GB) | 1993-01-13 | — | — | EP | claimed |
| US-5157114-A | Treatment of HIV infections | BURROUGHS WELLCOME CO. (US) | 1992-10-20 | — | — | US | claimed |
| WO-1992013527-A1 | WATER-DISPERSIBLE TABLETS | THE WELLCOME FOUNDATION LIMITED (GB) | 1992-08-20 | — | — | WO | claimed |
| EP-0356166-A2 | Therapeutic nucleosides | THE WELLCOME FOUNDATION LIMITED (GB) | 1990-02-28 | — | — | EP | claimed |
| EP-2488182-B1 | Treating neurotoxicity associated with combinations of 5-FU or its prodrugs and DPD inhibitors | ELION ONCOLOGY LLC (US) | 2017-07-19 | — | — | EP | disclosed |
| WO-2014089004-A1 | METHODS FOR TREATING 5-FLUOROURACIL PRODRUG NON-RESPONSIVE CANCER PATIENTS | ADHEREX TECHNOLOGIES, INC. (US) | 2014-06-12 | — | — | WO | disclosed |
| US-8658618-B2 | Methods for preventing or reducing neurotoxicity associated with administering DPD inhibitors in combination with 5-FU and 5-FU prodrugs | ADHEREX TECHNOLOGIES, INC. (US) | 2014-02-25 | — | — | US | disclosed |
| US-8541600-B2 | 11-aza, 11-thia and 11-oxa sterol compounds and compositions | Harbor Therapeutics, Inc. (US) | 2013-09-24 | — | — | US | disclosed |
| WO-1992013527-A1 | WATER-DISPERSIBLE TABLETS | THE WELLCOME FOUNDATION LIMITED (GB) | 1992-08-20 | — | — | WO | disclosed |
| WO-1992004901-A1 | URACIL REDUCTASE INACTIVATORS | THE WELLCOME FOUNDATION LIMITED (GB) | 1992-04-02 | — | — | WO | disclosed |
| WO-1992001452-A1 | ENZYME INACTIVATORS | THE WELLCOME FOUNDATION LIMITED (GB) | 1992-02-06 | — | — | WO | disclosed |
| EP-0356166-A2 | Therapeutic nucleosides | THE WELLCOME FOUNDATION LIMITED (GB) | 1990-02-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020150585-A1 | Use of imine-forming polysaccharides as adjuvants and immunostimulants | TLR1, ICOS, TLR2 | LMNA 4648/4885SMN1; SMN2 3571/4885TK1 1800/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.